This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
As of today (2024-05-06), Sutro Biopharma's share price is $3.89. Sutro Biopharma's Median PS Value is $0.00. Therefore, Sutro Biopharma's Price to Median PS Value for today is 0.00.
The historical rank and industry rank for Sutro Biopharma's Median PS Value or its related term are showing as below:
STRO's Price-to-Median-PS-Value is not ranked *
in the Biotechnology industry.
Industry Median: 0.67 * Ranked among companies with meaningful Price-to-Median-PS-Value only.
Sutro Biopharma Median PS Value Historical Data
The historical data trend for Sutro Biopharma's Median PS Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Sutro Biopharma's Median PS Value
For the Biotechnology subindustry, Sutro Biopharma's Price-to-Median-PS-Value, along with its competitors' market caps and Price-to-Median-PS-Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sutro Biopharma's Price-to-Median-PS-Value Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Sutro Biopharma's Price-to-Median-PS-Value distribution charts can be found below:
* The bar in red indicates where Sutro Biopharma's Price-to-Median-PS-Value falls into.
Sutro Biopharma Median PS Value Calculation
Sutro Biopharma's Median PS Value for today is calculated as
10-Year Median PS Ratio is 0.
Sutro Biopharma's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $2.533.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sutro Biopharma (NAS:STRO) Median PS Value Explanation
This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio
is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
It also assumes that over time the profit margin is constant. If a company increases its profit margin to a sustainable level, this value might under-estimate its value. If it has permanent declined profit margins, this may over-estimate the company's value.
Sutro Biopharma's Price to Median PS Value for today is calculated as
Price to Median PS Value
=
Share Price
/
Median PS Value
=
3.89
/
0.00
=
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sutro Biopharma Median PS Value Related Terms
Thank you for viewing the detailed overview of Sutro Biopharma's Median PS Value provided by GuruFocus.com. Please click on the following links to see related term pages.
Sutro Biopharma (Sutro Biopharma) Business Description
Sutro Biopharma Inc is clinical-stage drug discovery, development, and manufacturing company. It is mainly engaged in the development of biopharmaceutical products. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and non-Hodgkin lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
STRO has been successfully added to your 